Clinical Trial Termination or Withdrawal in Head and Neck Squamous Cell Carcinoma
In this study, HNSCC CTs were terminated early or withdrawn for a variety of reasons, most commonly due to strategic decisions or poor recruitment. Careful attention to trial characteristics associated with early failure is needed to overcome new barriers to drug development and adapt trial design to common reasons for failure.
Authors
- Alex S. Reznik (ORCID: https://orcid.org/0000-0001-8993-8617)
- Alessandro E. P. Villa (ORCID: https://orcid.org/0000-0002-4684-0027)
- Stephen T. Sonis (ORCID: https://orcid.org/0000-0001-6480-2625)
- Elizabeth Franzmann (ORCID: https://orcid.org/0000-0002-6171-9380)
- Janice J. Huang
Institutions
- Brigham and Women's Hospital (US)
- Baptist Hospital of Miami (US)
- Harvard University (US)
- University of Miami (US)
- University of California, San Francisco (US)
- Baptist Health South Florida (US)
- Prime Solutions Group (United States) (US)
- Dana-Farber Cancer Institute (US)
- Boston Sports & Shoulder Center (US)
Publication Details
- Journal
- JAMA Otolaryngology–Head & Neck Surgery
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1001/jamaoto.2025.4766
- Citations
- 1
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 53.14